病理生理学和治疗需要在非阻塞性多变性心肌病变症
Milind Y Desai1, Niccolo Maurizi2, Elena Biagini3
1HCM Center, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
JACC. Heart failure
|September 25, 2025
概括
增高性心肌病变 (HCM) 是一种影响全球许多人的心脏病. 本综述详细介绍了非阻塞性HCM,其多种影响,以及针对新疗法的当前研究.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 内部医学 内部医学
背景情况:
- 在全球范围内,高性心肌病 (HCM) 影响超过每500人中的1人.
- 非阻塞性HCM,包括30-70%的病例,是高度异质的.
- 它导致显著的发病率,包括心力衰竭和心律失常.
研究的目的:
- 为非阻塞性HCM提供全面的概述.
- 涵盖流行病学,自然史,遗传学,病理生理学和临床方面.
- 讨论当前的治疗方法和正在进行的临床试验.
主要方法:
- 这是一个叙事评论.
- 关于非阻塞性HCM的文献搜索.
- 综合现有关于条件的数据.
主要成果:
- 非阻塞性HCM呈现出各种临床表现.
- 遗传因素在它的病理生理学中起着至关重要的作用.
- 目前没有批准的药物疗法,但试验正在进行中.
结论:
- 由于其异质性和负担,非阻塞性HCM需要进一步研究.
- 了解它的自然历史和遗传学是关键.
- 目前正在进行的试验为未来的治疗策略提供了希望.
相关概念视频
Cardiomyopathy V: Interprofessional Care
338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
Cardiomyopathy III: Hypertrophic Cardiomyopathy
411
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
411
Cardiomyopathy II: Dilated Cardiomyopathy
470
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
470
Cardiomyopathy I: Introduction and Classification
504
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
504
Pathophysiology of Heart Failure
2.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.9K
Heart Failure II: Pathophysiology
730
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
730


